A clinical trial involving corticorelin was registered on October 7, 2026. The study is titled "Identification of Physiological Sleep Indices That Reflect Clinical Improvement and Reduction in Stress Biomarkers After Stellate Ganglion Block in Patients With Posttraumatic Stress Disorder (PTSD)." Its registry identifier is NCT07618611. The trial's current status is listed as not yet recruiting. No phase applies to this study, as it is designated phase NA. The listing indicates the trial will examine physiological sleep indices in relation to clinical improvement and stress biomarker reduction following stellate ganglion block in PTSD patients. No enrollment has begun according to the current status. No outcomes, results, or efficacy data have been posted at this time. The registry entry reflects only the trial's design and planned scope as of the listed date. Further updates would be expected as the study progresses toward recruitment and beyond. Readers interested in corticorelin can consult the compound overview for additional background and context on its approved uses and general profile.
Corticorelin-Linked Trial on PTSD Sleep Biomarkers Registered
See the full corticorelin overview
Source: https://clinicaltrials.gov/study/NCT07618611